39836667|t|Cerebral Amyloid Angiopathy in Alzheimer Disease: A Comparison Between Different Versions of the Boston Criteria.
39836667|a|OBJECTIVES: Cerebral amyloid angiopathy (CAA) is the main driver of amyloid-related imaging abnormalities (ARIAs) in Alzheimer disease (AD). We compared different versions of the Boston criteria for CAA diagnosis in AD. METHODS: This article presents a single-center analysis (outpatient neurodegenerative clinic) of patients with AD with mild cognitive impairment (MCI) or early dementia, meeting NIA-AA criteria and having biological amyloid confirmation (CSF or imaging). Two raters analyzed hemorrhagic (cerebral microbleeds, CMBs; cortical superficial siderosis, cSS) and nonhemorrhagic (severe centrum semiovale perivascular spaces, CSO-PVSs; multispot pattern white matter hyperintensities (WMHs)) markers following the original (V1.0), modified (V1.5), and latest (V2.0) Boston criteria. RESULTS: We included 75 patients (mean age 71.6 +- 8.1 years, 53% female, mean disease duration 2.6 +- 2.0 years, 91% MCI). White matter CAA markers were more common than hemorrhagic markers: 41 (55%) had severe CSO-PVSs, 28 (37%) had multispot WHMs, 12 (16%) had 1 lobar CMB, 9 had >=2 lobar CMBs (12%), 1 (1.3%) had focal cSS, and 5 (6.7) had disseminated cSS. The prevalence of possible and probable CAA was lowest with V1.0 (14.7% and 9.3%) than with V1.5 (13.3% and 13.3%) and V2.0 (42.7% and 26.7%) criteria. DISCUSSION: More than 1 in 4 patients with AD had probable CAA according to the V2.0 Boston criteria. These findings might inform future trials.
39836667	0	27	Cerebral Amyloid Angiopathy	Disease	MESH:D016657
39836667	31	48	Alzheimer Disease	Disease	MESH:D000544
39836667	126	153	Cerebral amyloid angiopathy	Disease	MESH:D016657
39836667	155	158	CAA	Disease	MESH:D016657
39836667	182	219	amyloid-related imaging abnormalities	Disease	MESH:C564543
39836667	221	226	ARIAs	Disease	MESH:C564543
39836667	231	248	Alzheimer disease	Disease	MESH:D000544
39836667	250	252	AD	Disease	MESH:D000544
39836667	313	316	CAA	Disease	MESH:D016657
39836667	330	332	AD	Disease	MESH:D000544
39836667	391	401	outpatient	Species	9606
39836667	431	439	patients	Species	9606
39836667	445	447	AD	Disease	MESH:D000544
39836667	458	478	cognitive impairment	Disease	MESH:D003072
39836667	480	483	MCI	Disease	MESH:D060825
39836667	494	502	dementia	Disease	MESH:D003704
39836667	512	518	NIA-AA	Disease	MESH:C566236
39836667	550	557	amyloid	Disease	MESH:C000718787
39836667	609	620	hemorrhagic	Disease	MESH:D006470
39836667	622	642	cerebral microbleeds	Disease	MESH:D002547
39836667	644	648	CMBs	Disease	
39836667	650	680	cortical superficial siderosis	Disease	MESH:D012806
39836667	682	685	cSS	Disease	
39836667	753	761	CSO-PVSs	Disease	MESH:D018458
39836667	781	810	white matter hyperintensities	Disease	MESH:D056784
39836667	812	816	WMHs	Disease	
39836667	934	942	patients	Species	9606
39836667	1028	1031	MCI	Disease	MESH:D060825
39836667	1047	1050	CAA	Disease	MESH:D016657
39836667	1081	1092	hemorrhagic	Disease	MESH:D006470
39836667	1122	1130	CSO-PVSs	Disease	MESH:D018458
39836667	1155	1159	WHMs	Disease	
39836667	1182	1185	CMB	Disease	
39836667	1203	1207	CMBs	Disease	
39836667	1234	1237	cSS	Disease	
39836667	1268	1271	cSS	Disease	
39836667	1313	1316	CAA	Disease	MESH:D016657
39836667	1454	1462	patients	Species	9606
39836667	1468	1470	AD	Disease	MESH:D000544
39836667	1484	1487	CAA	Disease	MESH:D016657

